CellAct Pharma GmbH
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CellAct Pharma GmbH
Deals Shaping The Medical Industry, September 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.
Deal Watch: WuXi/Gloria License PD-1 Inhibitor To Arcus For Up To $816m
WuXi Biologics and Harbin Gloria will get $18.5m up front for the Phase I asset GLS-010. Also, Cerecor divests depression drug to Janssen for up to $45m and Perrigo sells its API division for $110m in cash.
Mundipharma Acquires 'Smart' Chemo Drug From CellAct
Mundipharma has acquired a next-generation chemotherapy agent from German biotech CellAct to further expand its oncology portfolio.
Start-Up Previews (11/2009)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Inflammation: A Hot Space Gets Complicated," features profiles of CellAct Pharma, Kineta and Lycera. Plus these Start-Ups Across Health Care: BioLeap, Integrated Diagnostics, Nightingale-EOS, SBIO, Spirus Medical and Varix Medical.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.